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Rare chromosome abnormalities, prevalence and
prenatal diagnosis rates from population-based
congenital anomaly registers in Europe
Diana Wellesley*,1, Helen Dolk2, Patricia A Boyd3, Ruth Greenlees2, Martin Haeusler4, Vera Nelen5,
Ester Garne6, Babak Khoshnood7, Berenice Doray8, Anke Rissmann9, Carmel Mullaney10, Elisa Calzolari11,
Marian Bakker12, Joaquin Salvador13, Marie-Claude Addor14, Elizabeth Draper15, Judith Rankin16 and
David Tucker17
The aim of this study is to quantify the prevalence and types of rare chromosome abnormalities (RCAs) in Europe for 2000–2006
inclusive, and to describe prenatal diagnosis rates and pregnancy outcome. Data held by the European Surveillance of Congenital
Anomalies database were analysed on all the cases from 16 population-based registries in 11 European countries diagnosed
prenatally or before 1 year of age, and delivered between 2000 and 2006. Cases were all unbalanced chromosome
abnormalities and included live births, fetal deaths from 20 weeks gestation and terminations of pregnancy for fetal anomaly.
There were 10323 cases with a chromosome abnormality, giving a total birth prevalence rate of 43.8/10000 births. Of these,
7335 cases had trisomy 21,18 or 13, giving individual prevalence rates of 23.0, 5.9 and 2.3/10000 births, respectively
(53, 13 and 5% of all reported chromosome errors, respectively). In all, 473 cases (5%) had a sex chromosome trisomy, and
778 (8%) had 45,X, giving prevalence rates of 2.0 and 3.3/10000 births, respectively. There were 1737 RCA cases (17%),
giving a prevalence of 7.4/10000 births. These included triploidy, other trisomies, marker chromosomes, unbalanced
translocations, deletions and duplications. There was a wide variation between the registers in both the overall prenatal
diagnosis rate of RCA, an average of 65% (range 5–92%) and the prevalence of RCA (range 2.4–12.9/10000 births). In all,
49% were liveborn. The data provide the prevalence of families currently requiring specialised genetic counselling services in
the perinatal period for these conditions and, for some, long-term care.
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INTRODUCTION
Chromosome abnormalities account for approximately 15% of the
major congenital anomalies diagnosed before the age of 1 year in
Europe, and are associated with 25% of perinatal deaths due to
congenital anomalies.1 In the European Union in 2004, about one-
quarter of all early neonatal deaths were due to congenital anomalies,
and of these, in the European Surveillance of Congenital Anomalies
(EUROCAT) database regions, 18% were chromosomal.1 The most
common chromosome abnormalities are trisomies 21, 18 and 13, and
the sex chromosome abnormalities.2 Little detailed information is
available on rarer chromosome abnormalities diagnosed prenatally or
in infancy.
In the 1960s and 1970s, cytogenetic surveys of all newborns3–6
established the prevalence of babies born with chromosome abnorm-
alities surviving to live births, irrespective of whether they would
normally have been diagnosed in early infancy. Not all babies with
chromosome abnormalities surviving to live births are diagnosed
under normal health care conditions. Children with sex chromosome
abnormalities may not have problems requiring investigation until
later in life, if at all.7,8 Marker chromosomes are known to vary widely
phenotypically, with apparently normal babies at birth remaining
unkaryotyped.9–11 Thus, the prevalence from cytogenetic surveys
does not tell us the diagnosed prevalence among babies. On the other
hand, the advent of prenatal screening has led to earlier detection
of some babies with chromosome abnormalities who would not
survive to live births, and to the increased detection of chromosomal
abnormalities, which result in phenotypically normal children.
Since these cytogenetic surveys, average maternal age has risen
across Europe and with it the prevalence of chromosomal abnormal-
ities. In the last few decades, increasing recognition of microdeletions
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as a cause of structural anomalies and ease of detection using the PCR
and other techniques have led to more chromosomal abnormality
diagnoses that would not have been included in the cytogenetic
surveys. Taking all these factors together, it is impossible to extrapolate
from the cytogenetic surveys to find the current prevalence of chromo-
some abnormalities diagnosed prenatally or up to 1 year of life.
EUROCAT is a network of population-based congenital anomaly
registers in Europe.1,12 Full-member registries send case data on all
congenital anomalies in their region. Data are collected in a standar-
dised format and subjected to rigorous validation checks to ensure
high quality. EUROCAT surveys41.5 million births per year (24.3%
of the annual European birth population), including information on
live births, fetal deaths from 20 weeks gestation and terminations of
pregnancy for fetal anomaly (TOPFA). One of the main EUROCAT
objectives is to assess the prevalence of congenital anomalies and the
impact of prenatal screening.
The aim of this study is to assess the prevalence and types of rare
chromosome abnormalities (RCAs) detected prenatally or in the first
year of life, using population-based data from EUROCAT registers.
This study provides data useful for the planning of services for affected
children and their families, and to contribute to the ongoing debate as
to whether routine prenatal screening with increasingly sensitive
techniques may be leading to the overdiagnosis of some chromosome
abnormalities which have no, or minor, health consequences.13 The
wide variation in prenatal screening policies in Europe14 serves as a
‘natural experiment’ resulting in variation in the prevalence of
prenatally detected RCA.
METHODS
Full member registries were invited to participate in the study if their
cytogenetic reporting was complete. In all, 16 registries from 11 countries
agreed to take part. Most congenital anomaly registries cover a local region of
variable size and so represent only part of a country, this area is described in the
title of each registry, as shown in Table 1.
For the main analysis, cases were extracted from the EUROCAT central
database using the following selection criteria:
 Live birth, fetal death from 20 weeks gestation or TOPFA
 Birth year 2000–2006
An ICD-10 code of Q9* or D82.1 or an ICD-9 code of 758* (Codes Q9* and
758* are the codes assigned, in either system, to cover all cases with any
chromosome abnormality and D82.1 ensures that all cases with a diagnosis of
DiGeorge syndrome are also included).
A search was also made of the anomaly text fields to ensure all relevant cases
had been captured.
All chromosome abnormalities were extracted and categorized according to
the type of error, with a more detailed analysis performed on those cases with
an RCA. RCAs were defined as cases with triploidy, other trisomy, marker
chromosomes, unbalanced translocation, deletions and duplications, and
excluded trisomies 21,18,13, 45,X and sex chromosome trisomies.
RESULTS
Table 1 shows the countries and their contributing EUROCAT
registers, the number of births in 2000–2006 covered by participating
registries, the observed prevalence of both total chromosome abnorm-
alities and RCAs. The percentage of all cases with a chromosome
abnormality that were prenatally detected is also shown.
There were approximately 2.4 million births in the registry areas,
representing 9% of total births in the 11 countries, during the 7-year
study period, of which 10 323 were diagnosed as having a chromo-
some abnormality within the first year of life. The overall prevalence
rate of an unbalanced chromosome abnormality was 43.8/10 000
births, ranging from 25.6 in Antwerp to 75.1 in Paris.
The rate of RCA was 7.4/10 000 births with a range from 2.4 in
South East Ireland to 12.9 in Northern England. The percentage of
RCAs prenatally detected varied widely from 4.9% in South East
Ireland to 92.3% in Paris. Most centres, however, were nearer to the
average of 65.2%. The method of chromosome ascertainment is also
noted in Table 1, clarifying whether the register obtains routine
downloads of all data (preferred) or not.
Table 1 The number of cases and prevalence of all, and rare, chromosome abnormalities and the percent of these prenatally detected for each
EUROCAT register included in this study
Country
EUROCAT
register(s)
Number of births
in the EUROCAT
registry areas
2000–2006
Number of
all chromosome
abnormalities reported
to EUROCAT 2000–2006
% of all chromosome
abnormalities
prenatally detected
Prevalence of
all chromosome
abnormalities per
10 000 births
Number of
rare chromosome
abnormalities reported
to EUROCAT 2000–2006
Prevalence of
rare chromosome
abnormalities per
10000 births
Austria Styriaa 62 667 228 76.4% 36.4 35 5.6
Belgium Antwerpb 127 871 327 60.1% 25.6 47 3.7
Denmark Odensec 37 346 137 70.9% 36.7 22 5.9
England and Wales East Midlandsb 432 568 1564 68.6% 36.2 234 5.4
Northern England 214 037 1030 58.8% 48.1 277 12.9
Thames Valley 88 814 458 73.9% 51.6 66 7.4
Wales 222 991 946 66.6% 42.4 184 8.3
Wessex 185 616 983 63.7% 53.0 231 12.4
France Paris 247 661 1860 92.3% 75.1 226 9.1
Strasbourgb,d 64 276 285 81.8% 45.4 37 5.8
Germany Saxony-Anhaltb 123 241 366 54.6% 29.7 57 4.6
Ireland South East Irelandb 45 135 118 4.9% 26.1 11 2.4
Italy Emilia Romagna 218 178 797 80.9% 36.5 118 5.4
Netherlands N Netherlands 137 278 411 48.5% 29.9 73 5.3
Spain Barcelona 96 912 491 88.1% 50.7 61 6.3
Switzerland Vaud 50 275 322 83.8% 64.0 58 11.5
Total 2 354 668 10323 65.2% 43.8 1737 7.4
aData from 2000–2005 only.
bNo routine downloads from cytogenetic labs.
cOnly prenatal cytogenetic downloads.
dData from 2000–2004 only.
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Figure 1 gives the total number of all unbalanced chromosome
abnormalities with the rare ones classified as ‘other’. Figure 2 sub-
divides these rare abnormalities by type.
RCAs
Table 2 and Figure 2 summarise the results for each chromosome
abnormality group. These are described in more detail below.
Triploidy. There was a total of 296 cases of triploidy, giving a
prevalence rate of 1.26/10 000 births, of which 92% were prenatally
detected (Table 3). There was no association with increased maternal
age. Fewer than 5% were alive at birth.
Other trisomies (non-21, 18, 13). There were 58 full trisomies notified
to EUROCAT, none of whom survived. The trisomic chromosomes
were: 21% with chromosome 22, 11% each with chromosome 9 and
16 and 1 or 2% each with chromosomes 1, 4, 5, 7 and 12. They were
all identified by prenatal testing or at late fetal deaths (Z20 weeks). Of
the 141 mosaic trisomies (0.60/10 000 births), 78% were prenatally
detected (Table 3). Of these, 41% were liveborn, 7% resulted in a
All
chromosomes
10,323 cases
T21
5422 cases
53%
T18
1377 cases
13%
T13
536 cases
5%
Other
1737 cases
17%
45,X
778 cases
8%
Sex
Chromosome
Trisomies
473 cases
4%
47,XXX=134
47,XXY=274
47,XYY=65
Figure 1 All unbalanced chromosome cases, diagnosed o1 year of age, from 16 registers, 2000–2006.
All
chromosomes
10,323 cases
Other
1737
Triploidy
296 cases
1.26/10,000
Deletions
736 cases
3.13/10,000
Unbalanced
translocations
221 cases
0.94/10,000
Markers
101 cases
0.43/10,000
Other trisomies
202 cases
0.86/10,000
4p-
31 cases
5p-
35 cases
Ring deletions
31 cases
Microdeletions
299 cases
Duplications
165 cases
0.70/10,000
Other
deletions
340 cases
Other
16 cases
Full trisomy
58 cases
Mosaic
trisomy
141 cases
Additional ring
3 cases
Figure 2 Numbers, rates and categories of RCAs.
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stillbirth and 49% had a TOPFA. Details of which mosaic chromo-
some was involved were reported in 62%, with chromosomes 8 and 9
each accounting for 25% of these. In all, 33% of the prenatally
detected cases and 73% of those postnatally detected were reported
to have structural anomalies. There was no pattern to these anomalies
except perhaps for trisomy 9, where three cases had spina bifida and at
least two had a cleft palate.
Marker chromosomes. There were 101 additional marker chromo-
somes identified (a birth prevalence rate of 0.43/10 000 births), of
which 77 were prenatally detected, 9 diagnosed at birth, 1 after the 1st
week of life and 14 with age at diagnosis not recorded. Of the
prenatally diagnosed cases, 43 (56%) resulted in a TOPFA, 30
(39%) were liveborn, two were stillborn and in two the outcome is
unknown. In only 17 cases, the chromosomal origin of the marker was
reported, of these, nine were from chromosome 15 and three from
chromosome 22. Significant congenital anomalies, including cleft lip
and palate, diaphragmatic hernia, agenesis of the corpus callosum,
Dandy–Walker malformation, VSD and craniosynostosis, were
reported in 17 cases, but there were insufficient details to link these
to the marker detected. A further three cases had nuchal oedema
recorded. Cases were reported from 11 centres.
Unbalanced translocations. There were 221 unbalanced translocations
reported (0.94/10 000 births). Of these, 115 (52%) were diagnosed
prenatally, 33 (15%) within the first week of life, 15 (7%) between 1
week and 1 year, 6 (3%) at miscarriage and in 52 (24%) the time of
diagnosis was not reported. In all, 62% were liveborn. There was no
evidence that maternal age was linked to the prevalence of an unbalanced
translocation and the sex ratio of the fetus/baby was also within the
normal range. The origin of the translocation was specified in 49 cases. Of
these, 27% were de novo, 35% maternal, 20% paternal and 20% ‘familial’.
Of those prenatally detected, 35% were diagnosed by 14 weeks
gestation (number of inherited cases not known), 45% between 15
and 21 weeks and 7% Z22 weeks.
Deletions, not including microdeletions. There were 437 cases, giving a
prevalence rate of 1.86/10 000 births reported with a chromosome
deletion, including those configured as a ring, but not including
microdeletions. The vast majority of these would have been detected
by a routine karyotype, perhaps clarified by FISH, but array CGH was
not in regular use during the case years of this study. Forty-three
percent were detected prenatally, a quarter of these following first
trimester screening, about half due to anomalies detected at a routine
anomaly scan and the remainder after 24/40. Sixty-nine percent were
liveborn. There was no evidence that maternal age was linked to the
prevalence of a deletion and the sex ratio of the fetus/baby was also
within the normal range.
Microdeletions. A total of 299 microdeletions were reported, of
which 227 were cases of 22q11 deletion from nine centres, giving a
prevalence rate of 0.96/10 000 births. For the other microdeletions,
there were too few cases from too few centres to comment on
prevalence, the details are shown in Table 2.
22q11 deletion. Of the 227 cases reported with 22q11 deletion, 180
had a heart defect. Of these, 54 (30%) were Fallot’s tetralogy, 24 (13%)
Table 2 Summary of cases, live births, prevalence, prenatal detection rate and maternal age for each rare chromosome group
Type of chromosome error
No. of
cases
Liveborn
(%)
Total prevalence
per 10 000 births
% Prenatally
detected
% Maternal age
Z35years Other findings of interest
Triploidy 296 10 (3%) 1.26 92% 20%
Other trisomies (non-21,18,13) 202 0.86 82% 46% Of 63% full trisomies with chromosomal origin specified:
Full trisomies 58 0 21%¼T22, 11%¼T9, 11% ¼T16
Mosaic trisomies 141 58 (41%) Of 62% mosaic trisomies (MT) 25%¼MT 8, 22%¼MT 9
Markers 101 52 (52%) 0.43 77% 53% 53% chromosome 15 (Of 17 cases with chromosome specified)
Unbalanced translocations 221 138 (62%) 0.94 52% 12% 27% de novo, 73% ‘familial’ (Specified in 49 cases)
Deletions, not including
microdeletions (see Table 3)
437 261 (60%) 1.86 43% 23%
Microdeletions 299 269 (90%) (1.27)
22q11 227 197 0.96 38% 16%
7q11 (Williams) 26 26 3%
28 28 0%
15q11 (Prader–Willi) 0%
9 9 78%
15q11 (Angelman) 9 9
11p15 (Beckwith–Wiedemann)
Duplications 165 101 (61%) 0.70 48% 28% Of the 73% with chromosome specified: 14%¼chromosome 15,
6%¼chromosome 12, rest o5% (nil chromosome 21, Y)
Table 3 Gestational age at detection in those prenatally diagnosed
% Prenatally detected
Chromosome
abnormality
% Prenatally
detected % o14/40 % 14–21/40 % Z22/40%
% Gestation
unknown
Triploidy 92 18 53 7 22
Other trisomies 83 25 45 14 16
Markers 76 9 61 17 13
Unbalanced
translocations
52 35 45 7 13
Deletions 43 11 49 20 20
22q11 del 37 3 47 41 9
Duplications 48 14 51 18 17
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had truncus arteriosus and 28 (16%) had an abnormality of the aorta.
In all, 61 (34%) had a ventricular septal defect and 28 (16%) had an
atrial septal defect, some in association with additional cardiac
anomalies. Eighty-one percent of cases were liveborn (Table 2). In
all, 37% were prenatally detected (Table 3), of whom 84% had a heart
defect, 8% talipes, 4% cleft lip and palate, and 6% a cleft palate alone.
The number of familial cases is not recorded.
Duplications. There were 165 cases with a chromosomal duplication
(prevalence rate 0.7/10 000 births), of which 48% were detected
prenatally (Table 3). There were 23 cases of dup(15), of which 16
were female and 7 male. Ten cases were duplications of chromosome
12 and there were o10 cases of duplication from each of the other
chromosomes and none from chromosomes 21 and Y. In 44 cases, the
chromosomal origin was unspecified. Considering all chromosomes
together, the sex ratio and maternal age distribution were within the
normal range. 61% were liveborn.
Others. The 16 cases in this category include those with diagnoses,
such as chimera, hermaphrodite and non-specific microdeletion or
uniparental disomy. Of these, 10 were liveborn.
Survival. There were 899 live births, of which 40 were known to have
died within the first year of life, 778 were known to have survived
and in 81 one-year survival was unknown. This gives a prevalence of
3.3–3.7 children/10 000 births potentially in need of long-term care.
DISCUSSION
Population-based congenital anomaly register data are derived from
both prenatal and postnatal sources. With the advent of prenatal
screening in the first trimester, many fetuses that would have mis-
carried or been stillborn are diagnosed with a chromosome error. Our
rate of 43.6/10 000 births, for all chromosome abnormalities, is
therefore, as expected, higher than that found in newborn
studies3,15–17 where rates of 17–31/10 000 were found.
There are very few data on the frequency of the less common and
non-maternal age-dependent chromosome errors detected perinatally.
One other report using congenital anomaly register data is from Baena
et al18 who looked at all babies diagnosed prenatally or within 7 days
of life and found a rate of 26.2/10 000 births for all chromosome
abnormalities. The 6.6% cases that were classified as rare (deletions,
duplications, trisomies, unbalanced translocations, markers and
apparently balanced rearrangements with a congenital anomaly)
gave a prevalence rate of 1.7/10 000 births, much lower than our
figure of 7.4/10 000 births. Apart from the study by Baena et al, we are
aware of no other studies looking at the total prevalence of rare
chromosome errors, so the data will be compared with the published
subgroup findings.
Triploidy is estimated to occur in 1–2% of all clinically recognised
conceptions19 with two-thirds miscarrying before 15 weeks of gesta-
tion. Our rate of 1.26/10 000 births reflects this early loss and is very
close to the prevalence rate of 1.34/10 000 births from Hawaii.20
Regarding marker chromosomes, Liehr and Wiese21 reviewed 132
studies on small supernumerary marker chromosomes (sSMC) and
found an averaged prevalence rate of 7.5/10 000 births in unselected
prenatal cases and 4.4/10 000 births in consecutively studied new-
borns. Our rate of 0.43 is therefore lower than might be expected. A
recent study by Crolla et al9 showed that 68% are derived from
acrocentrics, and of these 51% are from chromosome 15. With
significant variability in the phenotype associated with many
sSMCs, it is likely that only those considered significant were reported
to the registers. This is supported by the high rate (17%) of anomalies
present in our prenatally detected cases and 30% in our postnatally
detected cases with a sSMC compared with a study by Warburton,10
who found that 13% of those detected by amniocentesis had one or
more anomaly. Our predominance of markers derived from chromo-
some 15, in the few that were further analysed, is entirely in keeping
with other reports.9,22,23
There are no comparable studies on the prevalence of non-21, 13 or
18 mosaic and non-mosaic trisomies, but Forabosco et al24 found a
rate of 0.22/10 000 births. Our rate of 0.86 included the 22% of cases
not reported to be detected prenatally. Mosaic trisomy 8 was the most
common diagnosis in liveborn cases with the chromosome of origin
specified, although many of these would be expected to be diagnosed
in later childhood and therefore not registered.
Duplications are rare abnormalities and there are no studies
offering a birth prevalence for this group of chromosome
abnormalities. Our rate of 0.7/10 000 births with a duplication
that represents 1.6% of all our reported chromosome abnormalities
therefore stands alone.
The reported prevalence of chromosomal deletions from congenital
anomaly register data ranges from 0.3 to 2/10 000 births18,25–28 with
newborn studies suggesting a similar rate of 0.5–1/10 000.3,15 More
recent studies include that of Forrester and Merz from Hawaii,27 who
looked at all deletions reported to a congenital anomaly register within
an 8-year period. In all, 4.7% of all chromosome abnormalities
reported were deletions, including microdeletions, giving a prevalence
of 1.99/10 000 births. Twenty-seven percent were diagnosed prenatally.
Just over 7% of all our chromosome abnormalities were deletions,
giving a rate of 3.27/10 000 births with 43% of our cases reported
prenatally.
Our data cover a more recent time period when the detection of
microdeletions is more routine and frequently considered clinically.
Forrester and Merz27 found 14% of their deletion cohort to have
22q11 deletion, whereas in our cohort the proportion was 31%.
Swerdlow et al29 analysed the mortality rate in all deletions ever
reported postnatally to all the UK cytogenetic laboratories. It is not
possible to derive a prevalence rate from these data, as only postnatally
detected cases were included, but 20% of their cases had a 22q11
deletion.
Genetic testing for 22q11 deletion became available in 1993–1994,
and increased awareness of this syndrome means that children with
congenital anomalies within the expected spectrum are now likely to
be diagnosed with this chromosome deletion. Oskarsdottir et al30
studied the incidence and prevalence of this condition in live births
in a hospital catchment area in Western Sweden for the period
1991–2000. Their 1.32–2.33/10 000 birth rates varied by district,
depending on experience and awareness. Our inclusive rate of 0.96/
10 000 births varied from 0.2–1.8/10 000 births for different registers
and reflects the largely perinatal ascertainment of cases by registers.
The rate found by Forrester and Merz27 was 0.28/10 000 births.
Other microdeletions are included in this report as they are an
RCA; however, as most of them were reported from only a few
registers, no prevalence figures can be given. The poor reporting is
likely to be due to the age of presentation of these conditions as many
are not detected perinatally. It may also be related to the variation in
genetic expertise available to individual registers.
There are some limitations to this study. Although the variation in
prevalence rates between registers may be due to real differences, there
are inherent local policy issues that contribute to these variations. For
instance, the low prevalence rate in Ireland in part reflects their
minimal rates of prenatal diagnosis as TOPFA is illegal, and in Paris
ascertainment only includes infants up to 1 week of age. Also relevant
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is the link between congenital anomaly registers and the cytogenetic
laboratories in their area of coverage. For those with regular and
routine downloads, complete ascertainment can be expected, but for
those registers with partial (for example, prenatal only) or no routine
reports, lower prevalence rates can be expected, which we generally
found to be the case (Table 1).
Reporting the prevalence rates by register as well as overall, allows
the use of comparable data for future studies, while maintaining the
spectrum offered by covering several regions of Europe.
Those chromosome abnormalities that lead to significant develop-
mental disability may be detected within the first year of life, but many
such children do not present until later. Most of the registers in this
study only collect cases that are diagnosed by one year of age, thus we
have excluded all cases diagnosed after this age for consistency.
Therefore, the figure of 7.4/10 000 births is certainly an underestimate
of the true prevalence of all RCAs in a population.
Only limited data about prenatal diagnosis are currently reported to
EUROCAT. Although there is robust information on whether a case
was prenatally detected or not, details such as the reason for karyotyp-
ing and associated anomalies are not recorded by all EUROCAT
registers.
The strength of this study is that EUROCAT registries are popula-
tion-based, use similar methodology and thus can provide data on
prevalence and prenatal diagnosis for rare anomalies. It also enables
comparisons between regions to be made.
In spite of the stated limitations of this study, these data provide the
only baseline prevalence figures currently available for health service
planning for the management and care of people with a rare
chromosome abnormality. The live birth prevalence rate of 3.7/
10 000 births of long-term survivors with an RCA is significant and
may be used to guide long-term healthcare for affected individuals.
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